Text Size
Santen Global

2024 News

Press Release

Santen New Drug Application Filing Accepted for Review in South Korea and Vietnam for the Use of STN1013001 (Cationic Emulsion of Latanoprost 50μg/mL) in Glaucoma
Santen and Arctic Vision execute a commercial collaboration agreement for ARVN001, a suprachoroidal space injection therapy for the treatment of uveitic macular edema
Santen launches Rhopressa® ophthalmic solution 0.02% (netarsudil mesylate), in South Korea, for the treatment of patients with open-angle glaucoma or ocular hypertension
Santen Announces Corporate Volunteer Partnership with Be My Eyes
Santen applies for manufacturing and marketing approval in Japan for STN1012600 ophthalmic solution (sepetaprost ophthalmic solution), a treatment for glaucoma and ocular hypertension with a novel mechanism of action for lowering intraocular pressure
Press Release

IR News

Santen Announces Completion of Share Buyback
Santen New Drug Application Filing Accepted for Review in South Korea and Vietnam for the Use of STN1013001 (Cationic Emulsion of Latanoprost 50μg/mL) in Glaucoma
Santen Announces Status of Share Buyback
【Updated】Corporate Governance Report
Santen and Arctic Vision execute a commercial collaboration agreement for ARVN001, a suprachoroidal space injection therapy for the treatment of uveitic macular edema
IR News

Information

Santen Providing Disaster Relief to Communities Impacted by Heavy Rain in Noto Peninsula
Cutting Back on Pouches and Medicine Bags Provided With Eye Drops -Santen’s Efforts to Reduce Single-Use Plastic to Decrease Our Environmental Footprint-
Santen Recognized for Longstanding Commitment to Nippon Lighthouse Guide Dog Training Program
17 Visually Impaired Children Participate in “17th Santen Brasaka Kids’ Camp in Kansai”
Santen selected as "The Sustainability Yearbook Member" by S&P Global in the United States
Information
News Archive
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved